Sarepta Therapeutics, Inc.SRPTNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+106.3%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
+106.3%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
37.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 999.60% |
| Q3 2025 | -105.58% |
| Q2 2025 | 144.79% |
| Q1 2025 | -733.85% |
| Q4 2024 | 230.19% |
| Q3 2024 | -573.16% |
| Q2 2024 | 106.17% |
| Q1 2024 | -342.90% |
| Q4 2023 | 52.35% |
| Q3 2023 | 6.16% |
| Q2 2023 | 41.63% |
| Q1 2023 | -126.64% |
| Q4 2022 | -42.22% |
| Q3 2022 | 2.77% |
| Q2 2022 | 33.96% |
| Q1 2022 | -245.00% |
| Q4 2021 | 76.41% |
| Q3 2021 | -13.91% |
| Q2 2021 | 39.49% |
| Q1 2021 | -3.34% |
| Q4 2020 | 26.72% |
| Q3 2020 | -121.36% |
| Q2 2020 | -117.14% |
| Q1 2020 | 483.28% |
| Q4 2019 | -142.91% |
| Q3 2019 | 14.65% |
| Q2 2019 | 45.97% |
| Q1 2019 | -19.45% |
| Q4 2018 | -8.03% |
| Q3 2018 | 3.36% |
| Q2 2018 | -228.74% |
| Q1 2018 | -14.84% |
| Q4 2017 | 46.36% |
| Q3 2017 | 32.00% |
| Q2 2017 | -47.09% |
| Q1 2017 | 28.74% |
| Q4 2016 | -34.01% |
| Q3 2016 | -40.04% |
| Q2 2016 | 28.68% |
| Q1 2016 | -94.06% |